Molecular Genetics Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India.
BMC Cancer. 2012 Jun 6;12:212. doi: 10.1186/1471-2407-12-212.
KIT is a proto-oncogene involved in diverse neoplastic processes. Aberrant kinase activity of the KIT receptor has been targeted by tyrosine kinase inhibitor (TKI) therapy in different neoplasias. In all the earlier studies, KIT expression was reported to be absent in meningiomas. However, we observed KIT mRNA expression in some meningioma cases. This prompted us to undertake its detailed analyses in meningioma tissues resected during 2008-2009.
Tumor tissues and matched peripheral blood samples collected from meningioma patients were used for detailed molecular analyses. KIT expression was ascertained immunohistochemically and validated by immunoblotting. KIT and KITLG transcript levels were discerned by reverse transcription quantitative real-time PCR (RT-qPCR). Similarly, KIT amplification and allele loss were assessed by quantitative real-time (qPCR) and validated by fluorescence in situ hybridization (FISH) on the neoplastic tissues. Possible alterations of the gene at the nucleotide level were analyzed by sequencing.
Contrary to earlier reports, KIT expression, was detected immunohistochemically in 20.6% meningioma cases (n = 34). Receptor (KIT) and ligand (KITLG) transcripts monitored by RT-qPCR were found to co-express (p = 0.048) in most of the KIT immunopositive tumors. 1/7 KIT positive meningiomas showed allele loss corroborated by reduced FISH signal in the corresponding neoplastic tissue. Sequence analysis of KIT showed M541L substitution in exon 10, in one of the immunopositive cases. However, its biological consequence remains to be uncovered.
This study clearly demonstrates KIT over-expression in the human meningiomas. The data suggest that up-regulated KIT transcription (p < 0.001), instead of gene amplification (p > 0.05), is a likely mechanism responsible for altered KIT expression. Thus, KIT is a potential candidate for detailed investigation in the context of meningioma pathogenesis.
KIT 是一种参与多种肿瘤过程的原癌基因。KIT 受体的异常激酶活性已成为不同肿瘤中酪氨酸激酶抑制剂(TKI)治疗的靶点。在所有早期研究中,脑膜瘤中均未检测到 KIT 表达。然而,我们在一些脑膜瘤病例中观察到 KIT mRNA 表达。这促使我们在 2008-2009 年期间对切除的脑膜瘤组织进行详细的分析。
使用脑膜瘤患者的肿瘤组织和配对的外周血样本进行详细的分子分析。通过免疫组织化学检测 KIT 表达,并通过免疫印迹进行验证。通过逆转录定量实时 PCR(RT-qPCR)检测 KIT 和 KITLG 转录本水平。同样,通过定量实时(qPCR)评估肿瘤组织中的 KIT 扩增和等位基因丢失,并通过荧光原位杂交(FISH)进行验证。通过测序分析基因在核苷酸水平上的可能改变。
与早期报道相反,免疫组织化学检测到 20.6%的脑膜瘤病例(n=34)存在 KIT 表达。通过 RT-qPCR 监测的受体(KIT)和配体(KITLG)转录本在大多数 KIT 免疫阳性肿瘤中共同表达(p=0.048)。在 1/7 的 KIT 阳性脑膜瘤中,发现等位基因丢失,相应的肿瘤组织中 FISH 信号减少。KIT 的序列分析显示,在一个免疫阳性病例中,exon10 中的 M541L 取代。然而,其生物学后果仍有待揭示。
本研究清楚地表明 KIT 在人类脑膜瘤中过度表达。数据表明,上调的 KIT 转录(p<0.001)而不是基因扩增(p>0.05)可能是导致 KIT 表达改变的机制。因此,KIT 是脑膜瘤发病机制研究的一个潜在候选基因。